Menumenu
  • Home
  • Oncology Publications

Oncology Publications

Oncology Publications

  • Chemotherapy Exposure and outcomes of Chronic Lymphoid Leukemia Patients.Abstract

    Kuiper J, Musingarimi P, Tapprich C, Penning-van Beest F, Gaudig M. J Clin Intensive Care Med. 2017 2 025-033.
  • Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.Abstract

    BACKGROUND: Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blocers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts

    Cardwell CR, Pottegard A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvan athan K, Cronin-Fenton D, DeSchutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K. Breast Cancer Res. 2016 Dec 01; 18 (1): 119.
  • Drug dispensings among elderly in the year before colon cancer diagnosis versus matched cancer-free controls.Abstract

    WHAT IS KNOWN AND OBJECTIVE: The concomitant use of multiple drugs is common among the general population of elderly. The aim of this study was to provide an overview of which drugs are dispensed to elderly in the year before colon cancer diagnosisand to compare this with cancer-free controls. METHODS: Data from the Eindhoven Cancer Registry were linked to the PHARMO Database Network

    van Erning FN, Zander s MM, Kuiper JG, van Herk-Sukel MP, Maas HA, Vingerhoets RW, Zimmerman DD, deFeyter EP, van dePoll ME, Lemmens VE. J Clin Pharm Ther. 2016 Oct; 41 (5): 538-45.
  • The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients.Abstract

    BACKGROUND: Aspirin use has been shown to lower incidence and mortality in cancer patients. The aim of this population-based study was to determine the effect of postdiagnosis low-dose aspirin use on survival of patients with oesophageal cancer. MEHODS: Patients with oesophageal cancer (1998-2010) were selected from the Eindhoven Cancer Registry and linked with outpatient pharmacy data regarding aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)

    van Staalduinen J, Frouws M, Reimers M, Bastiaannet E, van Herk-Sukel MP, Lemmens V, de Steur WO, Hartgrink HH, van de Velde CJ, Liefers GJ. Br J Cancer. 2016 Apr 26; 114 (9): 1053-9.
  • Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.Abstract

    OBJECTIVE: To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes. DESIGN: Retrospective cohort study using propensity score matched cohorts. SETTINGS: Healthcare databases from Finland, the Neherlands, Sweden, and the United Kingdom. Data comprised country specific datasets of linked records on prescriptions, hospitals, general practitioners, cancer, and deaths

    Korhonen P, Heintjes EM, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S. BMJ. 2016 354 i3903.
  • Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?.Abstract

    BACKGROUND: Metformin, statin and aspirin use seem associated with decreased mortality in cancer patients, though, without adjusting for one another. Independent associations of these drugs with overall mortality after colorectal cancer (CRC) diagnsis within glucose-lowering drugs (GLDs) users were assessed

    Zander s MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR, van dePoll-Franse LV. Br J Cancer. 2015 Jul 28; 113 (3): 403-10.
  • Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes.Abstract

    AIMS/HYPOTHESIS: Adherence to glucose-lowering drug (GLD) treatment regimens is crucial for metabolic control and improving prognosis. Because a diagnosis of cancer might have an impact on adherence to medication, this study explored changes in adhrence to GLDs following a cancer diagnosis. METHODS: All new users of GLDs between 1998 and 2011 who lived in the Eindhoven Cancer Registry-PHARMO Database Network catchment area were selected

    Zander s MM, Haak HR, van Herk-Sukel MP, van dePoll-Franse LV, Johnson JA. Diabetologia. 2015 May; 58 (5): 951-60.
  • Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database.Abstract

    Few data have been published on healthcare resource utilisation associated with chemotherapy-induced febrile neutropenia (FN) in Europe. Using the PHARMO record linkage system, we identified incident adult patients with a primary hospital dischargediagnosis of breast cancer (BC) or non-Hodgkin lymphoma (NHL) from 1998 to 2008

    Issa DE, Gelder blom H, Lugtenburg PJ, van Herk-Sukel MP, Houweling LM, DeLaOrden M, van der Werf-Langenberg ME, Nortier JW, deJong FA. Eur J Cancer Care (Engl). 2015 Mar; 24 (2): 232-41.
  • Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study.Abstract

    Preclinical data showed anticancer effects of statins in melanoma, but meta-analyses could not demonstrate a reduced melanoma incidence in statin users. Rather than preventing occurrence, statins might reduce growth and metastatic spread of melanoms and ultimately improve survival. In this population-based study, we investigated the relationship between statin use and survival of melanoma patients

    Livingstone E, Hollestein LM, van Herk-Sukel MP, van dePoll-Franse L, Joosse A, Schilling B, Nijsten T, Schaden dorf D, deVries E. Cancer Med. 2014 Oct; 3 (5): 1284-93.
  • Patterns of metachronous metastases after curative treatment of colorectal cancer.Abstract

    BACKGROUND: This study aimed to provide information on timing, anatomical location, and predictors for metachronous metastases of colorectal cancer based on a large consecutive series of non-selected patients. METHODS: All patients operated on withcurative intent for colorectal cancer (TanyNanyM0) between 2003 and 2008 in the Dutch Eindhoven Cancer Registry were included (N=5671)

    van Gestel YR, de Hingh IH, van Herk-Sukel MP, van Erning FN, Beerepoot LV, Wijsman JH, Slooter GD, Rutten HJ, Creemers GJ, Lemmens VE. Cancer Epidemiol. 2014 Aug; 38 (4): 448-54.